CEO Dan Hicklin (Werewolf)

Were­wolf pre­pares to bare its teeth in 1st tri­al for tar­get­ed cy­tokine tu­mor fight­ers with new round of in­vestor cash

Boston area biotech Were­wolf Ther­a­peu­tics launched in late 2019 with the goal of chas­ing nov­el im­mune sys­tem mod­u­la­tors to erad­i­cate sol­id tu­mors. Just over a year af­ter hit­ting the ground run­ning, Were­wolf has three can­di­dates in de­vel­op­ment and has its eyes set on the clin­ic with a new round of fund­ing.

Were­wolf on Thurs­day un­veiled a $72 mil­lion Se­ries B round to move its im­munother­a­pies, which tar­get the mi­croen­vi­ron­ments of sol­id can­cer tu­mors, to Phase I clin­i­cal proof-of-con­cept stud­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.